These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 3079198)

  • 21. [Is it possible to modify labyrinthine circulation?].
    Martin H; Martin C; Oudot J
    J Fr Otorhinolaryngol Audiophonol Chir Maxillofac; 1978 May; 27(5):331-9. PubMed ID: 149834
    [No Abstract]   [Full Text] [Related]  

  • 22. Rationale for and study design of the sulodexide trials in Type 2 diabetic, hypertensive patients with microalbuminuria or overt nephropathy.
    Lambers Heerspink HJ; Fowler MJ; Volgi J; Reutens AT; Klein I; Herskovits TA; Packham DK; Fraser IR; Schwartz SL; Abaterusso C; Lewis J;
    Diabet Med; 2007 Nov; 24(11):1290-5. PubMed ID: 17956455
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Milestone in the treatment of diabetic dyslipidemia: the DAIS Study].
    Forster T
    Orv Hetil; 2001 Jul; 142(29):1588-9. PubMed ID: 11494751
    [No Abstract]   [Full Text] [Related]  

  • 24. Effect of sulodexide on blood viscosity in patients with peripheral vascular disease.
    Castelluccio A; Bologna E
    Curr Med Res Opin; 1991; 12(5):325-31. PubMed ID: 2004545
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Rapid effect of glucuronyl glucosamine glycan sulfate on the blood levels of HDL-cholesterol in vascular diseases].
    Ferlito S; La Spina E; Cultrera E; Puleo F; Carrà G
    Arch Sci Med (Torino); 1982; 139(2):175-81. PubMed ID: 7138283
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [The problem of an antilipemic synergism between the action of nicotinic acid and the sulphated polyanion SP54 (author's transl)].
    Levy H
    Med Klin; 1974 Sep; 69(36):1441-7. PubMed ID: 4280008
    [No Abstract]   [Full Text] [Related]  

  • 27. The use of sulodexide in the treatment of peripheral vasculopathy accompanying metabolic diseases. Controlled study in hyperlipidemic and diabetic subjects.
    Pisano L; Moronesi F; Falco F; Stipa E; Fabbiani N; Dolfi R; Conoscenti E; Gloria R; Pepe R
    Thromb Res; 1986 Jan; 41(1):23-31. PubMed ID: 3515614
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Clinical study of moxisylyte citrate].
    Thénot A
    Clin Ter; 1970 Nov; 55(4):305-12. PubMed ID: 4397031
    [No Abstract]   [Full Text] [Related]  

  • 29. PoleStriding exercise and vitamin E for management of peripheral vascular disease.
    Collins EG; Edwin Langbein W; Orebaugh C; Bammert C; Hanson K; Reda D; Edwards LC; Littooy FN
    Med Sci Sports Exerc; 2003 Mar; 35(3):384-93. PubMed ID: 12618567
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Hemodynamic effects of ethaverine hydrochloride in patients with peripheral vascular disease.
    Asby GR; Stein M; Conrad MC; Michie DD
    Curr Ther Res Clin Exp; 1974 Oct; 16(10):1096-100. PubMed ID: 4215620
    [No Abstract]   [Full Text] [Related]  

  • 31. Peripheral vascular disease improved by clofibrate.
    Exp Med Surg; 1968; 26(4):277-9. PubMed ID: 5736504
    [No Abstract]   [Full Text] [Related]  

  • 32. A multicenter double blind controlled study of lipo-PGE1, PGE1 incorporated in lipid microspheres, in peripheral vascular disease secondary to connective tissue disorders.
    Mizushima Y; Shiokawa Y; Homma M; Kashiwazaki S; Ichikawa Y; Hashimoto H; Sakuma A
    J Rheumatol; 1987 Feb; 14(1):97-101. PubMed ID: 3553591
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clinical benefit and prolongation of platelet half-life induced by CG 4203, a stable PGI2-analogue.
    Kaliman J; Fitscha P; Barth H; Sinzinger H
    Prog Clin Biol Res; 1987; 242():469-77. PubMed ID: 3313421
    [No Abstract]   [Full Text] [Related]  

  • 34. Effects of sulodexide in patients with type 2 diabetes and persistent albuminuria.
    Heerspink HL; Greene T; Lewis JB; Raz I; Rohde RD; Hunsicker LG; Schwartz SL; Aronoff S; Katz MA; Eisner GM; Mersey JH; Wiegmann TB;
    Nephrol Dial Transplant; 2008 Jun; 23(6):1946-54. PubMed ID: 18089623
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [A double blind study of the new hypolipidemic agent pirozadil (722-D) using patients with ischemic heart disease (author's transl)].
    Cadierno Carpintero M; Emeterio Reig E; Soler Masana JM
    Med Clin (Barc); 1982 May; 78(9):386-9. PubMed ID: 7047927
    [No Abstract]   [Full Text] [Related]  

  • 36. Therapeutic defibrinogenation in peripheral vascular disease.
    Ernst E
    Int Angiol; 1985; 4(3):373-7. PubMed ID: 3913715
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Clinico-experimental contribution on the role of mucopolysaccharides in homeostasis of the microcirculation].
    Pasta V; Criscuolo A
    Ann Ital Chir; 1982; 54(6):565-73. PubMed ID: 6224450
    [No Abstract]   [Full Text] [Related]  

  • 38. Clinical, blood gas, and lactate changes in the course of the treatment of peripheral vascular disease with a hemodialysate.
    Rossano C; Weiner M; Haigis E
    Arzneimittelforschung; 1990 Nov; 40(11):1195-200. PubMed ID: 2085330
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Common questions in managing hyperlipidemia.
    Rosen IM; Sams RW
    Prim Care; 2006 Dec; 33(4):903-21. PubMed ID: 17169673
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Randomised, double blind, multicentre, placebo controlled study of sulodexide in the treatment of venous leg ulcers.
    Coccheri S; Scondotto G; Agnelli G; Aloisi D; Palazzini E; Zamboni V;
    Thromb Haemost; 2002 Jun; 87(6):947-52. PubMed ID: 12083500
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.